Hosted on MSN10h
Nammi Therapeutics doses first subject in trial of QXL138AM for multiple myeloma
Nammi Therapeutics has commenced the first in-human Phase I trial of QXL138AM by dosing the first subject for treating ...
Cure Today15h
FDA Receives Application Seeking Approval of Darzalex Faspro in Smoldering Myeloma
If approved by the FDA, Darzalex Faspro may be the first treatment for smoldering multiple myeloma as compared to treating the disease once it progresses.
Pharmabiz18h
Johnson & Johnson seeks US & EU approvals for Darzalex Faspro/Darzalex as subcutaneous monotherapy for high-risk smoldering multiple myeloma
“There remains an unmet need for early interventions and treatments that are both effective and well tolerated in people living with smoldering multiple myeloma at high-risk of progressing to active ...